Abstract:Prostate cancer (PCa) is the most common cancer in men and the fifth leading cause of cancer death worldwide. Unfortunately, castration-resistant prostate cancer (CRPCa) is incurable with surgical treat and prone to drug resistance. Therefore, it is of great importance to find a new target for treatment. LSD1 is up-regulated in PCa and related with prognosis. The high-expression LSD1 has been shown to be a potential target for treatment and is widely studied for its demethylase-activity. However, its demethylation-independent function remains to be elusive in PCa. Recent study shows that LSD1 can destabilize cancer suppressor protein FBXW7 without demethylation-function. Hence, we hope to investigate the impact of non-canonical function of LSD1 on PCa cell survival. We over-expressed FBXW7 gene through plasmid vector in LNCaP and PC3 cell lines and the result shows that up-regulated FBXW7 can suppress the viability of PC cell through suppressing oncoproteins, such as c-MYC, NOTCH-1. After FBXW7 function experiment on PC cell, we knock-down LSD1 gene in the same kinds of cell lines. In western blot assay, we detected that down-regulation of LSD1 will cause the increasing of FBXW7 protein level and decreasing of its targeting oncoproteins. And mRNA level of FBXW7 did not change significantly after LSD1 knock-down, which means LSD1 may destabilize FBXW7 by protein-protein interactions. Moreover, exogenous wild type LSD1 and catalytically deficient mutant K661A both can abrogate previous effect of LSD1 knock-down. Consequently, LSD1 may promote PC cell survival by destabilizing FBXW7 without its demethylase-activity. Next, we compared two kinds inhibitors, and found that SP-2509 (Allosteric inhibitor) treatment suppress the cancer cell survival by blocking the LSD1–FBXW7 interaction, which is an effect that GSK-2879552 (catalytic inhibitor) cannot achieve. This work revealed a pivotal function of LSD1 in PCa, and indicated a new direction of LSD1 inhibitor research for PCa treatment.

LSD1 Destabilizes FBXW7 and Abrogates FBXW7 Functions Independent of Its Demethylase Activity

LSD1 Destabilizes FBXW7 Independent of Its Demethylase Activity

LSD1 Promotes Prostate Cancer Cell Survival by Destabilizing FBXW7 at Post-Translational Level

Data from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination.

LSD1 Knockdown Reveals Novel Histone Lysine Methylation in Human Breast Cancer MCF-7 Cells

Supplementary Figure 2 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

OTUD7B Deubiquitinates LSD1 to Govern Its Binding Partner Specificity, Homeostasis, and Breast Cancer Metastasis

Supplementary Figure 1 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Lysine-specific Histone Demethylase 1 (LSD1): A Potential Molecular Target for Tumor Therapy

LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation

LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis Programs in Breast Cancer

Therapeutic potential of targeting LSD1/ KDM1A in cancers

LSD1 Coordinates with the SIN3A/HDAC Complex and Maintains Sensitivity to Chemotherapy in Breast Cancer.

The E239K mutation abolishes the suppressive effects of LSD1 on the migration and invasion of MCF7 cells

Supplemental Figure 4 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

LSD1 inhibitor hinders the demethylation of FOXA1 to inhibit prostate cancer progression

The Deubiquitinase USP28 Stabilizes LSD1 and Confers Stem-Cell-like Traits to Breast Cancer Cells

Demethylase-independent roles of LSD1 in regulating enhancers and cell fate transition

Pharmacological Inhibition of LSD1 for Cancer Treatment